Could Your Digital Twin Help Choose a Treatment?
Digital twins in clinical care promise to explore treatment possibilities through patient-informed computational models before implementation. FDA recognizes model-informed drug development as the use of biological and statistical models drawing on preclinical and clinical data to support regulatory decisions including dose selection, trial design, and safety investigation. Evidence supports narrowly scoped models addressing specific clinical questions rather than complete human simulations. Usefulness depends on whether the model improves decisions beyond available information, identifies data insufficiencies, and demonstrates validated performance beyond its construction dataset. Critical considerations include population applicability, transparency regarding predictions and limitations, and documented protocols for when patient reports diverge from model outputs. The most promising near-term applications may emerge from modest, well-defined successes: answering specific questions more reliably, selecting measurements more intelligently, or facilitating uncertainty discussion. Trust requires clarity about what the model predicts, for whom, over what timeframe, with documented accuracy evidence. Responsibility for interpretation must remain visible to care teams. Executives should distinguish marketing language about “complete digital twins” from evidence-supported model-informed applications with clearly defined purposes and validated performance in relevant populations.
When the Clinical Trial Comes Home
Decentralized clinical trials incorporating telehealth visits, home visits by remote personnel, and local healthcare provider involvement can reduce participant burden without relocating all activities from traditional research sites, according to FDA September 2024 final guidance. Trial design must balance convenience against safety, measurement quality, and participant support. A hybrid model allows appropriate activities in different settings while maintaining oversight and data integrity. Design considerations include identifying which visits require site attendance, clarifying logistics and equipment needs, and testing instructions with intended users. Convenience involves more than travel reduction; it encompasses total burden including tasks transferred to home settings, such as device management, software use, and privacy requirements. Access depends on measurable factors including awareness, eligibility, enrollment patterns, and retention across populations. Operational processes must ensure measurement validity, identify data collection failures, and enable follow-up when issues occur. The substantive value of home-based trial elements emerges from participant feedback on which burdens decreased and which new ones appeared, indicating whether decentralized activities actually improved participation feasibility. Executive implication: decentralized trials require rigorous design around observed participant needs rather than assumed convenience, with dependable data collection pathways supporting the research relationship across multiple settings.
Inclisiran access: the referral queue behind an infrequent injection
Inclisiran access requires operational infrastructure beyond convenient dosing. ORION-10 and ORION-11 trials (1,561 and 1,617 participants) demonstrated LDL-C lowering; FDA approved inclisiran in December 2021 on this evidence. The drug’s label specifies initial dose at month zero, repeat at month three, then every six months thereafter, requiring healthcare professional administration. A fictional clinic receiving 1,000 referrals over six months faces sequential handoffs: clinical assessment, coverage verification, appointment scheduling, and visit completion. Baseline workflow completion rates (80%, 75%, 80%, 90% respectively) yield approximately 432 expected initial visits; improving all four steps to 90%, 85%, 90%, 95% produces roughly 654 expected starts—a gain of 222 patients. However, this assumes downstream capacity exists; fixed appointment slots may simply shift queues. Starter cohorts demand distinct capacity planning: 432 baseline starters require 1,296 first-year administrations; 654 improved starters require 1,962 administrations. A 2,400-slot annual clinic cannot assume both new and maintenance visits fit without clustering effects, cancellations, and staff absence. A hypothetical $45,000 coordination project yields $39,973.50 additional contribution at $60 per completed administration across three incremental visits—insufficient recovery without explicit broader service goals. Financial modeling must account for inventory purchase timing versus payment collection to avoid funding gaps. Clinics should establish baseline referral resolution metrics, distinguish patient choice from operational failure, and observe actual queue constraints before expanding capacity. This analysis separates observed evidence (trial endpoints, label specifications) from operational scenarios and financial assumptions, all hypothetical.